<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081051</url>
  </required_header>
  <id_info>
    <org_study_id>AM 001</org_study_id>
    <nct_id>NCT04081051</nct_id>
  </id_info>
  <brief_title>Advancing Access to Diagnostic Innovation Essential for UHC and AMR Prevention</brief_title>
  <official_title>Impact of Improved Diagnostic Tools, Practices and Training and Communication on Acute Fever Case Management and Antibiotic Prescriptions for Children and Adolescents Presenting at Outpatient Facilities in Lower &amp; Middle Income Countries (LMICs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WHO, Special Programme for Research and Training in Tropical Diseases (TDR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate clinical outcomes and antibiotic prescription patterns following
      the use of diagnostic algorithms, point of care rapid diagnostic tests, and behaviour change
      interventions in cases of acute febrile illnesses in children, adolescents and adults
      presenting at out patient clinics in lower and middle income countries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale. 'Just-in-case' antibiotic prescribing practices is one of the
      causes of inadequate management of 'acute febrile illnesses' and AMR in Low- and
      Middle-income Countries (LMICs). At the same time, some people who would require antibiotic
      treatment do not get it. An improvement in case management and prescription practice might
      lead to a decrease in morbidity and mortality. Success will mean making significant steps
      toward achieving the dual goal of improving UHC and tackling AMR.

      The PICO question addressed is:

        1. Population; patients (children/ adolescent and adult) presenting to outpatient clinics /
           peripheral health centres in LMICs with acute febrile illness / Respiratory Tract
           Infection

        2. Intervention; combining available diagnostic tests, diagnostic aids/algorithms, clinic
           process flow and, training and communication

        3. Control; Compared to current practice

        4. Outcome; can we improve management of acute febrile illnesses and better target the use
           of antibiotics / reduce unnecessary antibiotic prescriptions as appropriate and feasible
           Primary objective(s) To evaluate the impact of a package of interventions (point of care
           [PoC] tests, clinical algorithm, clinic process flow, training and communication tools)
           on clinical outcomes and antibiotic prescriptions, with standard-of-care practices, in
           children and adolescents presenting with acute febrile illnesses (defined as fever with
           no focus or Respiratory Tract Infection lasting for no more than 7 days), at outpatient
           clinics Secondary objective(s)

      1. To improve the management of acute febrile illness 2. To promote rational and targeted use
      of antibiotics for acute febrile illness 3. To determine the aetiology of fever in patients
      presenting to outpatient facilities using available PoC diagnostic tests 4. To study the
      safety and feasibility of a package of interventions compared to current practice of care 5.
      To assess the effectiveness of training and communication tools to adherence to the
      prescribed treatment Primary endpoints (outcomes) 1. Proportion of outpatient cases of acute
      febrile illness with favourable outcome (defined as being alive and asymptomatic).

      2. antibiotic prescriptions rates for acute febrile illness in the clinic Secondary endpoints
      (outcomes) 1. Duration of time spent in the clinic 2. Proportion of patients treated for
      specific bacterial infection 3. Proportion of patients with disease specific diagnosis
      identified by PoC tests 4. Frequency of serious adverse event (SAE) within 7 days of
      recruitment 5. Frequency of unscheduled (unplanned) visit within 7 days of recruitment 6.
      Training and communication package uptake 7. Proportion of patients prescribed antibiotic at
      clinic who reported adherence to prescription on day 7 8. Proportion of patients who were not
      prescribed antibiotics at clinic who received antibiotics elsewhere between day 0 and day 7
      9. Behaviour Change Intervention Recommendations Trial design A multi-centre, open label, two
      arm, randomized-controlled trial Trial sites/setting This study will be conducted in
      outpatient departments and primary care clinics in Burkina Faso, Ghana, India, Myanmar, Nepal
      and Uganda.

      Trial population . The study population will consist of children, adolescents and adults
      presenting to the health care facility, or provider, with acute fever or history of fever

      Sample Size Approx. 10,000
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of acute febrile cases with favorable clinical outcomes at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Favorable defined as being alive and asymptomatic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiotic prescription rates in acute fever cases</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of antibiotic prescriptions for acute febrile illness in the clinic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with acute fever Diagnoses identified by point of care tests.</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of patients with disease specific diagnosis identified by PoC tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 7</time_frame>
    <description>Frequency of adverse events within 7 days of recruitment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in the clinic</measure>
    <time_frame>Day 0</time_frame>
    <description>Time spent in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of study participants who adhered to antibiotic prescriptions</measure>
    <time_frame>Day 7</time_frame>
    <description>Adherence to antibiotic prescriptions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Acute Febrile Illness</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care practices for acute febrile illness</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)</intervention_name>
    <description>Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting with fever with no focus/RTI:

               -  Children (6 months to &lt;12 years) and adolescents (12 years to less than 18 years
                  old) of both sexes .

               -  Presenting with an acute febrile illness defined as temperature of &gt;37.5Â°C or
                  history of fever within the last 7 days with no focus or suspected RTI.

               -  Parent/guardian providing written informed consent for their children if less
                  than 18 years of age.

               -  Obtain assent for adolescent between 12 and less than 18 years old

               -  Willing to provide blood and other samples and adhere to study procedures
                  explained in the consent forms following the protocol.

               -  Available and willing to return for follow-up visit at the health facility on day
                  7 (+/- 2 days).

        Exclusion Criteria:

          -  o Children and adolescents from 6 months to less than 18 years old presenting with
             chronic febrile illness (fever lasting more than 7 days).

               -  Patients with acute febrile illness outside the allowed age range for the site.

               -  Severely ill patients requiring hospital admission or referral as assessed by the
                  study clinicians.

               -  Anyone refusing consent to the study or not able to attend the health centre for
                  follow-up (adults, the children of parents/guardians, or adolescents who refuse
                  or are missed when asking for consent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piero Olliaro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Foundation For Innovative New Diagnostics ( FIND)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piero Olliaro, MD</last_name>
    <phone>+41227100984</phone>
    <email>piero.olliaro@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olawale Salami, MD</last_name>
    <email>olawale.Salami@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRSS-DRCO/Clinical Research Unit of Nanoro (CRUN)</name>
      <address>
        <city>Nanoro</city>
        <zip>BP 218</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <contact>
      <last_name>Halidou Tinto, PhD</last_name>
      <email>halidoutinto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Francois Kiemde, PhD</last_name>
      <email>kiemdefrancois@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Halidou Tinto, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shai-Osudoku District Hospital</name>
      <address>
        <city>Accra</city>
        <state>Dodowa</state>
        <country>Ghana</country>
      </address>
    </facility>
    <contact>
      <last_name>Rita Baiden, MD</last_name>
      <email>rita_baiden@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jan Swathya Sahyog</name>
      <address>
        <city>Ganiyari</city>
        <state>Chhattisgarh</state>
        <zip>495112</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Gajanan B Phutke, MBBS</last_name>
      <email>gajananphutke@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Naman Shah, MD</last_name>
      <phone>077532 44819</phone>
      <email>namankshah@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yogesh Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anju Kitaria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biswaroop Chatterjee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Cholera &amp; Enteric Diseases</name>
      <address>
        <city>Beliaghata</city>
        <state>Kolkata</state>
        <zip>700010</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Shanta Dutta, MD</last_name>
      <phone>033 2363 3373</phone>
      <email>shanta.niced@icmr.gov.in</email>
    </contact>
    <contact_backup>
      <last_name>Alok K Deb, PhD</last_name>
      <email>adeb02@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Agniva Majumad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumanjo Kanungo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>R D Gardi Medical College</name>
      <address>
        <city>Ujjain</city>
        <state>Madhya Pradesh</state>
        <zip>456006</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Pathak Ashish, MBBS</last_name>
      <phone>073682 61235</phone>
      <email>drashish.jpathak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manju Purohit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Post Graduate Insitute Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Neelam Taneja, MD</last_name>
      <phone>0172 274 7585</phone>
      <email>drneelampgi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gajinder K Dewan, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arun K Bansal, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kawaljeet S Sandha, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruby Jain, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Myanmar Oxford Clinical Research Unit (MOCRU), Medical Action Myanmar (MAM)</name>
      <address>
        <city>Yangon</city>
        <state>Bahan Township</state>
        <country>Myanmar</country>
      </address>
    </facility>
    <contact>
      <last_name>Frank Smithuis, MD</last_name>
      <email>frank.m.smithuis@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Myo Maung Maung Swe, MD</last_name>
      <email>myomgswe@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Smithuis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myo Maung Maung Swe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Patan Academy of Health Sciences</name>
      <address>
        <city>Lalitpur</city>
        <state>Lagankhel</state>
        <zip>44700</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <contact>
      <last_name>Buddha Basnyat, MD</last_name>
      <email>buddhabasnyat@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abhishek Giri, MD</last_name>
      <email>giriabhishek@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Buddha Basnyat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abhishek Giri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease research collaboration</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>James Kapisi, MD</last_name>
      <email>kapisij@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Heidi hopkins, MD</last_name>
      <email>hhopkins@lshtm.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>James Kapisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Hopkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Ghana</country>
    <country>India</country>
    <country>Myanmar</country>
    <country>Nepal</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>to be discussed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

